Drug intelligence / Profile preview

haploidentical hematopoietic stem cells (KIR-HLA selected)

Development stage: Unknown
Lead developer: Memorial Sloan Kettering Cancer Center
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Haploidentical hematopoietic stem cells (KIR-HLA selected) refers to an allogeneic cell therapy protocol developed by Memorial Sloan Kettering Cancer Center for the treatment of high-risk hematologic malignancies. This intervention involves the transplantation of unmodified bone marrow-derived hematopoietic stem cells from a partially HLA-mismatched (haploidentical) related donor. The core of the therapy is a novel donor selection algorithm that prioritizes donors based on specific Killer Immunoglobulin-like Receptor (KIR) and Human Leukocyte Antigen (HLA) genetic profiles. This selection is designed to maximize the alloreactivity of donor-derived natural killer (NK) cells against the recipient's malignant cells, thereby enhancing the graft-versus-leukemia (GVL) effect. The protocol is typically administered following a conditioning regimen of melphalan, fludarabine, and thiotepa, and is being evaluated for various conditions including acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), and myelodysplastic syndromes (MDS).

Other names: haploidentical hematopoietic stem cells-Memorial Sloan Kettering Cancer Center-acute lymphoid leukemia-acute myeloid leukemia-myelodysplastic syndromes-chronic myeloid leukemia-Hodgkin lymphoma-non-Hodgkin lymphoma-chronic lymphocytic leukemia-myelofibrosis-chronic myelomonocytic leukemiaKIR-Based Donor Selection in Haploidentical HCTPartially HLA-Mismatched Related Donor Hematopoietic Stem Cell Transplantation Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection

Beyond the preview

Go deeper on haploidentical hematopoietic stem cells (KIR-HLA selected).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on haploidentical hematopoietic stem cells (KIR-HLA selected).

Explore the full profile